Hydroxocobalamin Alternova (Hydroxocobalamin)

Hydroxocobalamin serves as a precursor that is intracellularly reduced to methylcobalamin and adenosylcobalamin, the biologically active cofactors for methionine synthase and methylmalonyl‑CoA mutase. These enzymes are essential for DNA synthesis, myelin formation, and conversion of homocysteine to methionine, thereby correcting the metabolic defects caused by cobalamin deficiency.

The specific dose and dosing schedule of Hydroxocobalamin Alternova are determined by the prescribing clinician based on the patient’s clinical condition, severity of deficiency, and response to therapy. Healthcare providers select the appropriate amount and frequency of intramuscular or subcutaneous administration in accordance with current medical guidelines.

Safety data for hydroxocobalamin in pregnancy and lactation are limited, but vitamin B12 is essential for fetal development and maternal health. Use is generally considered when the potential benefit outweighs any unknown risk, and the decision should be made by a qualified healthcare professional after evaluating the individual’s situation.

To place an order, visit the product page for Hydroxocobalamin Alternova on gnhindia.com and submit an enquiry with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing a quotation, confirming availability, shipping conditions (including cold‑chain if needed), and handling import documentation.

Hydroxocobalamin is a hydroxylated form of cobalamin that is converted to the active co‑factors methylcobalamin and adenosylcobalamin, offering a longer plasma half‑life than cyanocobalamin. Compared with cyanocobalamin, it may provide more sustained cobalamin levels and is often preferred for injectable therapy in patients with severe deficiency or malabsorption.

Hydroxocobalamin Alternova should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Maintaining the cold‑chain ensures stability and potency until the time of administration.

The product is supplied for parenteral use and must be injected by a qualified healthcare professional. Administration is performed either intramuscularly or subcutaneously, depending on clinical judgment and patient factors. Proper aseptic technique and correct injection site selection are essential to minimize local reactions.

Although generally well tolerated, serious adverse events can occur, including anaphylactic reactions, severe hypotension, and rare immune‑mediated skin conditions such as Stevens‑Johnson syndrome. Prompt recognition of these signs and immediate medical intervention are critical. Patients should be observed after injection, especially during the first administration.

Hydroxocobalamin is contraindicated in individuals with known hypersensitivity to hydroxocobalamin or any component of the formulation. Patients with a history of severe allergic reactions to injectable vitamin B12 products should avoid its use. Clinical assessment is required to determine suitability for therapy.